Revance TherapeuticsRVNC
13F holders, Q1 2025 (March 31)1holders −172
0new positions
168sold out
$4.94avg. 13F price*
At the end of Q1 2025, 1 institutions reported holding Revance Therapeutics Inc. (RVNC) in their 13F filings, down 172 from Q4 2024. 0 opened new positions and 168 sold out. The largest holder was DekaBank Deutsche Girozentrale ($425K).
- Company
- Revance Therapeutics Inc.
- CUSIP
- 761330109
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 168 | $247.3M |
All 13F filers, Q4 2024 → Q1 2025: 81,348,704 shares sold, net −81,348,704 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| DekaBank Deutsche Girozentrale | 0.00% | No change | 86,100 | $425K |
"% of holder's portfolio" is RVNC's weight in each manager's 13F, not the share of Revance Therapeutics Inc. the manager owns.